Management of Dyslipidemias: Enhancing Lipid Modification to Reduce Cardiovascular Risk: 2nd Edition

Dear Colleagues,

We are pleased to announce the release of the second volume of the Special Issue “Management of Dyslipidemias: Enhancing Lipid Modification to Reduce Cardiovascular Risk” (https://www.mdpi.com/journal/jcm/special_issues/TZ49Z25FAH).

Cardiovascular disease (CVD) is a leading cause of death in several developed countries, with low-density lipoproteins (LDL), among other atherogenic lipoproteins such as lipoprotein remnants (e.g., very low-density lipoproteins (VLDL) and chylomicron remnants), being considered as the key causal factors or contributors to the development of atherosclerosis. 

Continued research and new observational studies as well as interventional trials have revealed that beyond LDL-Cholesterol (LDL-C) levels, the identification of markers (biological, environmental, and genetic) associated with remnant metabolism could enhance CV risk prediction and optimize treatment strategies. However, many conditions of rare and severe causes of atherogenic lipid disorders, such as homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia, and severe hypertriglyceridemia, pose significant challenges for lipid management. Patients with these conditions cannot attain the desired thresholds of lipid parameters and continue to experience CV events, despite being treated with maximally tolerated lipid-lowering therapies (LLT). 

LLTs are evolving rapidly, and several agents have now included new inhibitors such as PCSK9, ANGPLT3, and APOC3 as targets. Future directions might also involve additional therapies derived from new mechanisms of action or signalling pathways that will potentially allow for the development of new classes of drugs targeting lipoprotein metabolism for CVD prevention. The impact of other fat-related disorders, such as non-alcoholic steatohepatitis (NASH), which is shown to be associated with increased risk of CV events, is also worth mentioning; however, the underlying mechanisms between NASH and CVD in respect to their targeted interventions still remain unknown.

We take this opportunity to extend an invitation to researchers and clinical practitioners to contribute to a Special Issue of the Journal of Clinical Medicine titled, ‘Management of Dyslipidemias: Enhancing Lipid Modification to Reduce Cardiovascular Risk.’ We will accept submissions of original research, comprehensive review articles, and innovative protocols that highlight the recent research progress, including, but not limited to, novel mechanistic pathways and/or the identification of emerging avenues for therapies aimed at refining CV risk management.

Dr. Daniel Gaudet
Dr. Etienne Khoury
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardiovascular disease
• dyslipidemia
• lipoprotein remnant
• emerging lipid-lowering therapies
• rare and severe causes of atherogenic lipid disorders
• cardiovascular risk-related biomarkers
• drug safety and efficacy

• Management of Dyslipidaemias: Enhancing Lipid Modification to Reduce Cardiovascular Risk in Journal of Clinical Medicine (9 articles)